Cancer Research8d
PI3K/mTOR Dual Inhibitor GSK458 and Arsenic Trioxide Exert Synergistic Antitumor Effects against Ovarian Clear-Cell Carcinoma
1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical ...
pharmaphorum2d
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop
That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FiercePharma6d
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
Yahoo Finance26d
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Moderna reported preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia.
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
Benzinga.com7d
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
Guidance: GSK expects 2025 sales to grow between 3% and 5%, with core earnings per share growing between 6% and 8%, including the benefit from the share buyback. Specialty Medicines sales are ...
Yahoo Finance7d
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...
The Motley Fool UK5d
Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing ... solid but not spectacular at 3.9%.Glaxo’s full-year 2024 dividend ...
Yahoo Finance6d
Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?
The GSK (LSE: GSK) share price was causing me a lot of aggro ... The trailing dividend yield‘s solid but not spectacular at 3.9%.Glaxo’s full-year 2024 dividend will be 61p. The board’s forecasting ...
FiercePharma29d
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
How do Sanofi CEO Paul Hudson and GSK CEO Emma Walmsley—who lead two of ... The company's vaccine portfolio generated more than $3 billion in the U.S. during the first nine months of 2024.